Suppressive effect upon carboplatin hypersensitivity reaction via pegylated liposomal doxorubicin combination therapy

Background Occurrence of hypersensitivity reaction (HSR) in patients having received multiple doses of carboplatin has been reported. Several studies demonstrated reduction of carboplatin-associated HSR with in combination with pegylated liposomal doxorubicin (PLD). The objective of this study was t...

Full description

Saved in:
Bibliographic Details
Published in:International journal of clinical oncology 2020-09, Vol.25 (9), p.1718-1725
Main Authors: Shimada, Kyoko, Nagao, Shoji, Suzuki, Kazuhiro, Shibutani, Takashi, Yamamoto, Kasumi, Jimi, Tomoatsu, Yano, Hiroko, Kitai, Miho, Shiozaki, Takaya, Yamaguchi, Satoshi
Format: Article
Language:English
Subjects:
Cancer Research
Carboplatin
Clinical medicine
Combination therapy
Doxorubicin
Fallopian tube
Gastric cancer
Hypersensitivity
Medical records
Medicine
Medicine & Public Health
Oncology
Original Article
Ovarian cancer
Patients
Peritoneum
Surgical Oncology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Occurrence of hypersensitivity reaction (HSR) in patients having received multiple doses of carboplatin has been reported. Several studies demonstrated reduction of carboplatin-associated HSR with in combination with pegylated liposomal doxorubicin (PLD). The objective of this study was to determine the suppressive effect on carboplatin-induced HSR via combined treatment with PLD within clinical practice. Methods We reviewed the medical records of women with primary or recurrent ovarian, fallopian tube, or peritoneal cancer treated with carboplatin containing regimen at our hospital between January 2009 and March 2019. We compared the incidence of carboplatin-induced HSR among patients who received more than one cycle of PLD plus carboplatin (PLD-C) therapy (i.e., PLD-C group) versus patients who never received PLD-C therapy (non-PLD-C group). Results A total of 414 women were included in this study (48: PLD-C group, 366: non-PLD-C group). Carboplatin-induced HSR occurred in 34 total patients (8.2%) [1/48 (2.1%) in the PLD-C group and 33/366 (9.0%) in the non-PLD-C group], with a median cycle number of carboplatin administration at onset of HSR being 9. Incidences of carboplatin-induced HSR within the PLD-C versus non-PLD-C group at the 8th, 12th, and 16th cycles of carboplatin administration were 2.2% vs 11.2%, 2.2% vs 28.6%, and 2.2% vs 39.1%, respectively [hazard ratio: 19.2 (95% confidence interval: 9.82–39.4), p  
ISSN:1341-9625
1437-7772
DOI:10.1007/s10147-020-01706-w